Founder and CEO, Shanghai Medicilon Inc.

Dr. Chen is the founder and CEO of Shanghai Medicilon Inc. The company provides preclinical chemistry, ADMET and biology CRO services to pharmaceutical and biotech companies. Medicilon has built a fully integrated drug R&D technology platform to provide high quality preclinical and IND filing services for CFDA and US FDA submissions since 2004. Dr. Chen previously served as Director of Pharmaceutical Department at the Parker Hughes Cancer Center of Parker Hughes Institute, and Staff Investigator at the Department of Pharmacokinetics and Metabolism of Vertex Pharmaceuticals in the US for over seven years. Currently Dr. Chen serves as a Chinese governmental funding reviewer for drug discovery programs in several Hi-Tech Parks in Shanghai, Xiamen, and Wuhan. He also serves as Associate Director for the Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacological Society, a committee member for the Pharmacokinetics and Drug Metabolism Section of Chinese Pharmacological Society, and Adjunct Professor at China Pharmaceutical University. He has won several awards, including the Excellent Returnee Award and the 1000 Talents Plan Award from Chinese government, Research Excellence Award from Oklahoma State University, and Excellent Teacher Award from China Pharmaceutical University. He received his Ph.D. in Pharmacology and Toxicology from Oklahoma State University, postdoctoral training at Pharmaceutical Department of St. Jude Children’s Research Hospital, and B.S. and M.S. degrees from China Pharmaceutical University.

CHUN-LIN CHEN, PhD, EMBA